Dr. Mehmet Oz, Donald Trump’s pick to run the Centers for Medicare and Medicaid Services, could face many different and serious conflicts with his business interests if he is confirmed to run the agency.
The Washington Post reports that Oz, who has a long history of promoting questionable medical cures and diet solutions, also has business ties to pharmaceutical companies such as Novo Nordisk, the manufacturer of Ozempic. If Oz is confirmed to head the Centers for Medicare and Medicaid Services, his decisions would have considerable effects on these businesses.
Oz founded Sharecare, a digital health and media company, with Oprah Winfrey and WebMD founder Jeff Arnold in 2009. Novo Nordisk was a client of Sharecare. Being in charge of Medicare and Medicaid, two taxpayer-funded health care programs, would call into question whether he’d be affected by lobbying efforts from Big Pharma, particularly over weight-loss drugs like Ozempic.
Oz has repeatedly touted the benefits of Ozempic on his TV show as well as his website. He has also promoted Wegovy, another similar drug. Both are manufactured by Novo Nordisk, and the company has been lobbying the federal government to cover the drugs through Medicare and Medicaid.
The Biden administration proposed covering the weight-loss drugs last week, which raises the question of whether the incoming Trump administration will do the same. Such a move would raise a conflict within the administration between Oz and Trump’s nominee to run the Department of Health and Human Services, Robert F. Kennedy Jr., who has attacked pharmaceutical companies for selling drugs like Ozempic.
“They’re counting on selling it to Americans because we’re so stupid and so addicted to drugs,” Kennedy told Fox News in October.
There’s also Oz’s long history of touting questionable medical cures and diet solutions, which undercuts his medical credibility and even resulted in a congressional hearing. Will Oz’s quackery, as well as his business interests, affect his confirmation? In the Trump administration, after all, conflicts of interest are routinely ignored when money is involved.
